These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12186531)

  • 1. Effect of angiotensin-converting enzyme inhibitors on progression of nondiabetic renal disease.
    Jafar TH; Schmid CH; Levey AS
    Ann Intern Med; 2002 Aug; 137(4):298-9. PubMed ID: 12186531
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials.
    Schrier RW; Estacio RO
    Ann Intern Med; 2001 Jul; 135(2):138-9. PubMed ID: 11453714
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin converting enzyme inhibitors in nondiabetic renal disease.
    Maschio G; Marcantoni C
    Curr Opin Nephrol Hypertens; 1998 May; 7(3):253-7. PubMed ID: 9617554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
    Jafar TH; Schmid CH; Landa M; Giatras I; Toto R; Remuzzi G; Maschio G; Brenner BM; Kamper A; Zucchelli P; Becker G; Himmelmann A; Bannister K; Landais P; Shahinfar S; de Jong PE; de Zeeuw D; Lau J; Levey AS
    Ann Intern Med; 2001 Jul; 135(2):73-87. PubMed ID: 11453706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group.
    Giatras I; Lau J; Levey AS
    Ann Intern Med; 1997 Sep; 127(5):337-45. PubMed ID: 9273824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitor for slowing progression of diabetic and nondiabetic kidney disease.
    Myers BD; Boothroyd D; Olshen RA
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S66-70. PubMed ID: 11443771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease.
    Adarkwah CC; Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Apr; 11(2):215-23. PubMed ID: 21476823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Angiotensin converting enzyme inhibitors in renal diseases].
    Shestakova MV; Kutyrina IM
    Kardiologiia; 2002; 42(9):74-9. PubMed ID: 12494080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summaries for patients. Using a type of blood pressure medicine, angiotensin-converting enzyme inhibitors, to prevent worsening of kidney disease unrelated to diabetes.
    ACE Inhibition in Progressive Renal Disease Study Group
    Ann Intern Med; 2001 Jul; 135(2):S-21. PubMed ID: 11463005
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of angiotensin-converting enzyme inhibitors in patients with diabetic and nondiabetic chronic renal diseases: a need for reassessment.
    Jaichenko J; Fudin R; Shostak A; Gotloib L
    Nephron; 1998 Nov; 80(3):367-8. PubMed ID: 9807055
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases.
    Mimran A; Ribstein J
    Am J Hypertens; 1994 Sep; 7(9 Pt 2):73S-81S. PubMed ID: 7818839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive chronic nephropathy. With special emphasis on the influence of angiotensin converting enzyme inhibition.
    Kamper AL
    Dan Med Bull; 1998 Apr; 45(2):181-94. PubMed ID: 9587702
    [No Abstract]   [Full Text] [Related]  

  • 13. ONTARGET still OFF-TARGET?
    Lambers Heerspink HJ; de Zeeuw D
    Circulation; 2011 Mar; 123(10):1049-51. PubMed ID: 21357820
    [No Abstract]   [Full Text] [Related]  

  • 14. Remission of renal disease: recounting the challenge, acquiring the goal.
    Brenner BM
    J Clin Invest; 2002 Dec; 110(12):1753-8. PubMed ID: 12488422
    [No Abstract]   [Full Text] [Related]  

  • 15. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
    Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials.
    Shunan F; Jiqing Y; Xue D
    J Renin Angiotensin Aldosterone Syst; 2018; 19(4):1470320318803495. PubMed ID: 30296880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of systemic hypertension in the progression of nondiabetic renal disease.
    Marcantoni C; Jafar TH; Oldrizzi L; Levey AS; Maschio G
    Kidney Int Suppl; 2000 Apr; 75():S44-8. PubMed ID: 10828761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-angiotensin inhibitors in stage 4 chronic kidney disease.
    Hirsch S
    Kidney Int; 2006 Nov; 70(10):1880; author reply 1880-1. PubMed ID: 17080165
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions.
    Keane WF; Anderson S; Aurell M; de Zeeuw D; Narins RG; Povar G
    Ann Intern Med; 1989 Sep; 111(6):503-16. PubMed ID: 2491421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is ACEI superior to ARB for CKD?
    Imai E
    Intern Med; 2006; 45(4):179-81. PubMed ID: 16543686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.